Acadia Pharmaceuticals | ACAD - Ordinary Share Capital



Acadia Pharmaceuticals reported $167.36M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.


Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 167.36M 167.35M Jun/2025
ALKERMES USD 165.05M 163.25M Jun/2025
Alnylam Pharmaceuticals USD 130.98M 129.67M Jun/2025
Biogen USD 146.6M 146.5M Jun/2025
BioMarin Pharmaceutical USD 192M 191.81M Jun/2025
Bristol-Myers Squibb USD 2.04B 1.74B Jun/2025
Corcept Therapeutics USD 105.29M 105.15M Jun/2025
Cytokinetics USD 119.6M 119.48M Jun/2025
Eisai JPY 282.12M 44.7B Jun/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Incyte USD 194.12M 193.93M Jun/2025
J&J USD 3.12B 0 Mar/2025
Moderna USD 389M 388.96M Jun/2025
Neurocrine Biosciences USD 99M 0 Jun/2025
Pfizer USD 5.68B 5.2B Jun/2025
Prothena USD 53.83M 53.29M Jun/2025
PTC Therapeutics USD 79.38M 79.3M Jun/2025
Sarepta Therapeutics USD 97.71M 97.7M Jun/2025
Ultragenyx Pharmaceutical USD 96.35M 2.45M Jun/2025
Vertex Pharmaceuticals USD 256.3M 253.7M Jun/2025